1003-3734
2013 Issue 23
bian zhe tui jian
wang yu mei ;
wang yu mei ;
..............page:2702
..............page:2702
mei guo sheng wu lei si wu zhi dao cao an jie du fda 2012 nian 02 yue 09 ri fa bu ban ben
zhang ming ping ;
zhang ming ping ;
..............page:2707-2710
WINDOW OF NEW DRUGS
ben kan ;
ben kan ;
..............page:2711-2712
..............page:2713-2716
Pharmacology and clinical evaluation of transdermal patch of buprenorphine for relieving moderate to severe pain
XU Jian-guo;WANG Nan;Department of Anesthesiology;Nanjing General Hospital of Nanjing Military Command;PLA;School of Medicine;Nanjing University;
XU Jian-guo;WANG Nan;Department of Anesthesiology;Nanjing General Hospital of Nanjing Military Command;PLA;School of Medicine;Nanjing University;
..............page:2717-2720
Comparison and reflection of several exploratory clinical trial approaches
SHAO Rong;ZHAO Ye;China Pharmaceutical University;
SHAO Rong;ZHAO Ye;China Pharmaceutical University;
..............page:2721-2724
Correlation analysis on resource allocation of drug safety supervision and pharmaceutical economic development
CHENG Zhi-fang;WANG Guang-ping;JIANG Bin;Maternal and Child Health Hospital of Fangshan District;Shanghai Institute for Food and Drug Safety;School of Pharmaceutical Sciences;Peking University;
CHENG Zhi-fang;WANG Guang-ping;JIANG Bin;Maternal and Child Health Hospital of Fangshan District;Shanghai Institute for Food and Drug Safety;School of Pharmaceutical Sciences;Peking University;
..............page:2725-2729+2744
Analysis of relative efficiency in Chinese pharmaceutical industry based on data envelopment analysis
WU Chao;QIU Jia-xue;International Pharmaceutical Business School of China Pharmaceutical University;
WU Chao;QIU Jia-xue;International Pharmaceutical Business School of China Pharmaceutical University;
..............page:2730-2734
Analysis on recent years’ registration applications of new Chinese herbal active ingredient drugs in China
ZHANG Xiao-dong;WANG Hai-nan;LIU Lu;Center for Drug Evaluation;China Food and Drug Administration;Department of Cosmetic and Drug Registration;China Food and Drug Administration;
ZHANG Xiao-dong;WANG Hai-nan;LIU Lu;Center for Drug Evaluation;China Food and Drug Administration;Department of Cosmetic and Drug Registration;China Food and Drug Administration;
..............page:2735-2738
Synthesis and antitumor activities of gareinia glycosides
WANG Yang;ZHANG Qi-jing;LIU Ju;LIU Yang;HAN Shuang;ZHANG Qiu-shi;CHEN Ye;ZHOU Yun-peng;College of Pharmacy;Liaonning University;
WANG Yang;ZHANG Qi-jing;LIU Ju;LIU Yang;HAN Shuang;ZHANG Qiu-shi;CHEN Ye;ZHOU Yun-peng;College of Pharmacy;Liaonning University;
..............page:2739-2744
Investigation of compatible stability of commonly used traditional Chinese medicine injections for blood-activating and stasis-resolving
WU Yu-jie;WANG Yue-hua;HE Guo-rong;FANG Lian-hua;DU Guan-hua;Beijing Key Laboratory of Drug Targets Identification and Drug Screening;Institute of Materia Medica;Chinese Academy of Medical Sciences and Peking Union Medical College;State Key Laboratory of Bioactive Substances and Functions of Natural Medicines;Institute of Materia Medica;Chinese Academy of Medical Sciences and Peking Union Medical College;
WU Yu-jie;WANG Yue-hua;HE Guo-rong;FANG Lian-hua;DU Guan-hua;Beijing Key Laboratory of Drug Targets Identification and Drug Screening;Institute of Materia Medica;Chinese Academy of Medical Sciences and Peking Union Medical College;State Key Laboratory of Bioactive Substances and Functions of Natural Medicines;Institute of Materia Medica;Chinese Academy of Medical Sciences and Peking Union Medical College;
..............page:2745-2750
..............page:2750
Development of nuclear magnetic resonance method for analyzing chemical structures of the group A Neisseria meningococcal capsular polysaccharides
LI A-ni;YU Xu-bo;LUO Shu-quan;HU Hao;WU Bing;ZHAO Zhi-qiang;XIE Gui-lin;Lanzhou Institute of Biological Products Co.;Ltd.;
LI A-ni;YU Xu-bo;LUO Shu-quan;HU Hao;WU Bing;ZHAO Zhi-qiang;XIE Gui-lin;Lanzhou Institute of Biological Products Co.;Ltd.;
..............page:2751-2758+2785
Concerns of the safety evaluation of antibody-drug conjugates
ZONG Ying;MAO Yu;ZHANG Xiao-fang;YUAN Bo-jun;LU Guo-cai;Center for Evaluation of Drug Safety;Second Military Medical University;
ZONG Ying;MAO Yu;ZHANG Xiao-fang;YUAN Bo-jun;LU Guo-cai;Center for Evaluation of Drug Safety;Second Military Medical University;
..............page:2759-2764+2778
Research progress of non-steroidal anti-inflammatory drugs as anti-tumor drugs
YE Wen-feng;HE Cong-fa;LI Jia-ming;XU Qin-long;Department of Pharmacy;Anhui University of Traditional Chinese Medicine;Anhui Key Laboratory of Traditional Chinese Medicine;
YE Wen-feng;HE Cong-fa;LI Jia-ming;XU Qin-long;Department of Pharmacy;Anhui University of Traditional Chinese Medicine;Anhui Key Laboratory of Traditional Chinese Medicine;
..............page:2765-2770
Progress in research of anti-hepatitis B virus drugs
WANG Chen-yin;HUANG Zheng-ming;Department of Clinical Pharmacology;302 Hospital of PLA;Guiyang College of Traditional Chinese Medicine;
WANG Chen-yin;HUANG Zheng-ming;Department of Clinical Pharmacology;302 Hospital of PLA;Guiyang College of Traditional Chinese Medicine;
..............page:2771-2774
Progress in research of the biological activity of amentoflavone
ZHANG Zhen;WANG Feng;Ningxia Medical University;Incubation Base of National Key Laboratory for Cerebrocranial Diseases;General Hospital of Ningxia Medical University;
ZHANG Zhen;WANG Feng;Ningxia Medical University;Incubation Base of National Key Laboratory for Cerebrocranial Diseases;General Hospital of Ningxia Medical University;
..............page:2775-2778
Systematic evaluation for the effect of probiotic combined with probiotic on bacterial infection in liver transplant recipients
WEI Xiao-chen;ZHU Li-qin;WANG Chun-ge;Tianjin First Central Hospital;
WEI Xiao-chen;ZHU Li-qin;WANG Chun-ge;Tianjin First Central Hospital;
..............page:2779-2785
Comparison of 10-day and 14-day furazolidone-containing quadruple salvage therapies for Helicobacter pylori eradication
ZHENG Xiao-li;XU Le;Department of Gastroenterology;Beijing Hospital;
ZHENG Xiao-li;XU Le;Department of Gastroenterology;Beijing Hospital;
..............page:2786-2788+2821
Overview of constructing methods for the composite endpoint evaluation index in clinical trials
GUO Zheng-mei;YAO Chen;YAN Xiao-yan;Peking University First Hospital;Peking University Clinical Research Institution;
GUO Zheng-mei;YAO Chen;YAN Xiao-yan;Peking University First Hospital;Peking University Clinical Research Institution;
..............page:2789-2796+2830
Pharmacokinetics of mono-PEGylated Ophiopogonis Radix polysaccharide in rats with normal and ischemic myocardium
YAO Chun-xia;SHI Xiao-li;LIN Xiao;SHEN Lan;FENG Yi;College of Chinese Materia Medica;Shanghai University of Traditional Chinese Medicine;Engineering Research Center of Modern Preparation Technology of Traditional Chinese Medicine of Ministry of Education;Shanghai University of Traditional Chinese Medicine;
YAO Chun-xia;SHI Xiao-li;LIN Xiao;SHEN Lan;FENG Yi;College of Chinese Materia Medica;Shanghai University of Traditional Chinese Medicine;Engineering Research Center of Modern Preparation Technology of Traditional Chinese Medicine of Ministry of Education;Shanghai University of Traditional Chinese Medicine;
..............page:2797-2801
Effect of ginkgo ketone ester dispersible tablet on blood rheology of rats with acute blood stasis
WANG Li-chao;LIU Xin-guang;WANG Qi;QI Lian-wen;State Key Laboratory of Natural Medicines;China Pharmaceutical University;
WANG Li-chao;LIU Xin-guang;WANG Qi;QI Lian-wen;State Key Laboratory of Natural Medicines;China Pharmaceutical University;
..............page:2802-2804+2836
Caffeine inhibits the bioactivities of glioblastoma stem cells in vitro
FENG Hong-jiang;LIU Jie;JIANG Ning-peng;LI Bin;Liaocheng People’s Hospital;Shandong Institute of Scientific & Technical Information;Shandong Institute for Food and Drug Control;
FENG Hong-jiang;LIU Jie;JIANG Ning-peng;LI Bin;Liaocheng People’s Hospital;Shandong Institute of Scientific & Technical Information;Shandong Institute for Food and Drug Control;
..............page:2805-2808
Synthesis of telavancin
MA Shuai;JIA Jing-yu;YUAN Hong;CAO Sheng-hua;Sichuan Industrial Institute of Antibiotics;China National Pharmaceutical Group Corporation;
MA Shuai;JIA Jing-yu;YUAN Hong;CAO Sheng-hua;Sichuan Industrial Institute of Antibiotics;China National Pharmaceutical Group Corporation;
..............page:2809-2812
Graphical synthetic routes of edoxaban tosilate hydrate
LIU Yong-qiang;ZHANG Tao;ZHONG Jing-fen;Shanghai Institute of Pharmaceutical Industry;
LIU Yong-qiang;ZHANG Tao;ZHONG Jing-fen;Shanghai Institute of Pharmaceutical Industry;
..............page:2813-2816
Identification of pearl powder from Zhejiang by scanning electron microscope and X-ray diffraction analysis
LI Hui;HAN Mo;ZHU Fei-ye;SONG Jie;ZHANG Chun-chun;Zhejiang Chinese Medical University;
LI Hui;HAN Mo;ZHU Fei-ye;SONG Jie;ZHANG Chun-chun;Zhejiang Chinese Medical University;
..............page:2817-2821
Multifunctional dry powder formulations for pulmonary drug delivery
XU En-yu;YANG Mei;GUO Jing;SONG Shuang;JIANG Jun-feng;XU Ying;LI Hao-ying;School of Chemistry and Chemical Engineering;Liaoning Normal University;Biomanufacturing Research Centre;School of Mechanical and Electrical Engineering;Soochow University;Testing and Analysis Centre;Soochow University;
XU En-yu;YANG Mei;GUO Jing;SONG Shuang;JIANG Jun-feng;XU Ying;LI Hao-ying;School of Chemistry and Chemical Engineering;Liaoning Normal University;Biomanufacturing Research Centre;School of Mechanical and Electrical Engineering;Soochow University;Testing and Analysis Centre;Soochow University;
..............page:2822-2826
Analysis of the necessity of conducting pharmacokinetic study in the elderly
LI Min;HU Xin;LI Ke-xin;Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation;Department of Pharmacy;Beijing Hospital;
LI Min;HU Xin;LI Ke-xin;Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation;Department of Pharmacy;Beijing Hospital;
..............page:2827-2830
Cost-effectiveness analysis of tafluprost versus latanoprost in the treatment of primary open-angle glaucoma
HU Chun-yang;HAN Sheng;CHEN Lu-jia;ZHANG Mu-yu;HONG Dong-zhe;YANG Zhao;SHI Lu-wen;School of Pharmaceutical Sciences;Peking University;School of Public Health;Peking University;International Research Center for Medicinal Administration;Peking University;
HU Chun-yang;HAN Sheng;CHEN Lu-jia;ZHANG Mu-yu;HONG Dong-zhe;YANG Zhao;SHI Lu-wen;School of Pharmaceutical Sciences;Peking University;School of Public Health;Peking University;International Research Center for Medicinal Administration;Peking University;
..............page:2831-2836